Liquidia (NASDAQ:LQDA) Stock: Insider Sanjeev Khindri Sells 1,101 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,101 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $31,356.48. Following the completion of the transaction, the insider owned 64,846 shares in the company, valued at approximately $1,846,814.08. This represents a 1.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 3.1%

Shares of LQDA traded down $0.86 on Tuesday, hitting $26.81. 3,092,611 shares of the stock traded hands, compared to its average volume of 5,078,983. Liquidia Corporation has a one year low of $21.94 and a one year high of $93.61. The company has a market capitalization of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61. The business has a 50 day simple moving average of $63.40 and a 200 day simple moving average of $61.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the prior year, the business posted ($0.49) earnings per share. The business’s revenue for the quarter was up 1842.1% on a year-over-year basis. As a group, equities analysts forecast that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LQDA has been the subject of a number of recent analyst reports. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research report on Friday, July 24th. Stephens set a $130.00 price target on shares of Liquidia in a report on Friday, July 24th. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Weiss Ratings raised shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Finally, BTIG Research downgraded shares of Liquidia from a “buy” rating to a “neutral” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $83.69.

Institutional Trading of Liquidia

Large investors have recently modified their holdings of the company. Globeflex Capital L P purchased a new stake in Liquidia during the second quarter valued at $175,000. Nykredit A S purchased a new position in Liquidia in the second quarter worth about $177,000. Fluent Financial LLC purchased a new position in Liquidia in the second quarter worth about $287,000. WINTON GROUP Ltd purchased a new position in Liquidia in the second quarter worth about $335,000. Finally, Fulcrum Equity Management bought a new stake in shares of Liquidia during the 2nd quarter valued at about $399,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).